Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,287 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05309668 | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN(SPRINKLE) | active not recruiting | Phase 1 / Phase 2 | 36 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT05450744 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)(IPAX-2) | active not recruiting | Phase 1 | 12 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY |
| 3 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT05671510 | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors(PRESERVE-003) | active not recruiting | Phase 3 | 630 | OncoC4, Inc.INDUSTRY | 12 | Aug 13, 2026 | clinicaltrials |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01) | active not recruiting | Phase 3 | 510 | Olema Pharmaceuticals, Inc.INDUSTRY | 26 | Aug 13, 2026 | clinicaltrials |
| NCT07353957 | Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Merus B.V.INDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT07696715 | Timing of Immunotherapy in Melanoma(TIME-NL) | recruiting | N/A | 170 | Radboud University Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02300766 | Cerebellar Mutism Syndrome Study | recruiting | — | 2,000 | Rigshospitalet, DenmarkOTHER | 14 | Aug 12, 2026 | clinicaltrials |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | Phase 3 | 6,430 | Mats HeymanOTHER | 15 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT03391778 | Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | enrolling by invitation | Phase 1 | 250 | USWM CT, LLCINDUSTRY | 8 | Aug 11, 2026 | clinicaltrials |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma(FIGHT-302) | terminated | Phase 3 | 167 | Incyte CorporationINDUSTRY | 19 | Aug 11, 2026 | clinicaltrials |
| NCT03967223 | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors(IGNYTE-ESO) | active not recruiting | Phase 2 | 103 | USWM CT, LLCINDUSTRY | 7 | Aug 11, 2026 | clinicaltrials |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12) | active not recruiting | Phase 3 | 453 | Mirati Therapeutics Inc.INDUSTRY | 24 | Aug 11, 2026 | clinicaltrials |
| NCT04739761 | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer(DESTINY-B12) | active not recruiting | Phase 3 | 506 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05916313 | A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 | recruiting | Phase 1 | 20 | Boehringer IngelheimINDUSTRY | 6 | Aug 11, 2026 | clinicaltrials |
| NCT06131398 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 77 | AmgenINDUSTRY | 11 | Aug 11, 2026 | clinicaltrials |
| NCT06551324 | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).(MEVPRO-1) | active not recruiting | Phase 3 | 600 | PfizerINDUSTRY | 23 | Aug 11, 2026 | clinicaltrials |
| NCT07100730 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma(IPAX BrIGHT) | recruiting | Phase 3 | 50 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT07436858 | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer | not yet recruiting | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05382325 | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | active not recruiting | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT06222489 | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT | recruiting | Phase 2 | 16 | The Netherlands Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06298552 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis(ADAPT SERON) | active not recruiting | Phase 3 | 119 | argenxINDUSTRY | 22 | Aug 10, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT07336446 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs(ANDROMEDA) | recruiting | Phase 1 / Phase 2 | 300 | AstraZenecaINDUSTRY | 8 | Aug 10, 2026 | clinicaltrials |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients(COMPETE) | active not recruiting | Phase 3 | 324 | ITM Solucin GmbHINDUSTRY | 14 | Aug 7, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT04099251 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma(CheckMate76K) | active not recruiting | Phase 3 | 790 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 7, 2026 | clinicaltrials |
| NCT05999994 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer(CAMPFIRE) | recruiting | Phase 2 | 105 | Eli Lilly and CompanyINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT02453282 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)(MYSTIC) | active not recruiting | Phase 3 | 1,118 | AstraZenecaINDUSTRY | 17 | Aug 6, 2026 | clinicaltrials |
| NCT02489084 | Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP)(HANS) | completed | — | 2,000 | University Medical Center GroningenOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
| NCT01081951 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | active not recruiting | Phase 2 | 162 | AstraZenecaINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | recruiting | Phase 1 / Phase 2 | 680 | Daiichi SankyoINDUSTRY | 18 | Aug 5, 2026 | clinicaltrials |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma | active not recruiting | Phase 2 | 124 | Acerta Pharma BVINDUSTRY | 10 | Aug 4, 2026 | clinicaltrials |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma(EPCORE™FL-2) | active not recruiting | Phase 3 | 1,095 | GenmabINDUSTRY | 32 | Aug 4, 2026 | clinicaltrials |
| NCT06476184 | Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery(SALVOVAR) | recruiting | Phase 3 | 250 | ARCAGY/ GINECO GROUPOTHER | 4 | Aug 4, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT06960577 | Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) | recruiting | Phase 3 | 150 | AstraZenecaINDUSTRY | 7 | Aug 4, 2026 | clinicaltrials |
| NCT03843359 | A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors | terminated | Phase 1 | 97 | GlaxoSmithKlineINDUSTRY | 8 | Aug 3, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT07360834 | Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome(PREDI-LYNCH) | not yet recruiting | N/A | 2,000 | UNICANCEROTHER | 9 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT03383458 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation(CheckMate 9DX) | active not recruiting | Phase 3 | 545 | Bristol-Myers SquibbINDUSTRY | 25 | Jul 31, 2026 | clinicaltrials |
| NCT04557098 | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-1) | active not recruiting | Phase 2 | 194 | Janssen Research & Development, LLCINDUSTRY | 11 | Jul 31, 2026 | clinicaltrials |
| NCT04617925 | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis(EMN27) | completed | Phase 2 | 35 | Stichting European Myeloma NetworkNETWORK | 6 | Jul 31, 2026 | clinicaltrials |
| NCT05217446 | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer(SEAMARK) | active not recruiting | Phase 2 | 108 | PfizerINDUSTRY | 15 | Jul 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials